Cargando…

Analytic Morphomics in Myositis-Related Interstitial Lung Disease

PURPOSE: Interstitial lung disease (ILD) is the most common non-musculoskeletal manifestation of idiopathic inflammatory myopathies (IIM). Identification of body composition change may enable early intervention to improve prognosis. We investigated muscle quantity and quality derived from cross-sect...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Mahony, Alexander T., Henry, Patrick J., Coghlan, Patrick, Waldron, Michael, Crowley, Claire, Ryan, David, Moore, Niamh, Bennett, Deirdre M., O’Connor, Owen J., Maher, Michael M., Henry, Michael T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444650/
https://www.ncbi.nlm.nih.gov/pubmed/37458801
http://dx.doi.org/10.1007/s00408-023-00637-3
_version_ 1785093995503812608
author O’Mahony, Alexander T.
Henry, Patrick J.
Coghlan, Patrick
Waldron, Michael
Crowley, Claire
Ryan, David
Moore, Niamh
Bennett, Deirdre M.
O’Connor, Owen J.
Maher, Michael M.
Henry, Michael T.
author_facet O’Mahony, Alexander T.
Henry, Patrick J.
Coghlan, Patrick
Waldron, Michael
Crowley, Claire
Ryan, David
Moore, Niamh
Bennett, Deirdre M.
O’Connor, Owen J.
Maher, Michael M.
Henry, Michael T.
author_sort O’Mahony, Alexander T.
collection PubMed
description PURPOSE: Interstitial lung disease (ILD) is the most common non-musculoskeletal manifestation of idiopathic inflammatory myopathies (IIM). Identification of body composition change may enable early intervention to improve prognosis. We investigated muscle quantity and quality derived from cross-sectional imaging in IIM, and its relationship to ILD severity. METHODS: A retrospective cohort study assessing IIM of ILD patients (n = 31) was conducted. Two datasets separated in time were collected, containing demographics, biochemical data, pulmonary function testing and thoracic CT data. Morphomic analysis of muscle quantity (cross-sectional area) and quality (density in Hounsfield Units) on thoracic CT were analysed utilising a web-based tool allowing segmentation of muscle and fat. Bilateral erector spinae and pectoralis muscle (ESM&PM) were measured at defined vertebral levels. RESULTS: FVC and D(L)CO decreased but within acceptable limits of treatment response (FVC: 83.7–78.7%, p < 0.05, D(L)CO 63.4–60.6%, p < 0.05). The cross-sectional area of the PM and ESM increased (PM: 39.8 to 40.7 cm(2), p = 0.491; ESM: 35.2 to 39.5 cm(2), p = 0.098). Density significantly fell for both the PM and ESM (PM: 35.3–31 HU, p < 0.05; ESM: 38–33.7, p < 0.05). Subcutaneous fat area increased from 103.9 to 136.1 cm(2) (p < 0.05), while the visceral fat area increased but not reaching statistical significance. The change in PM density between time points demonstrated an inverse correlation with D(L)CO (p < 0.05, R =  − 0.49). CONCLUSION: Patients with IIM ILD demonstrated significant body composition changes on CT imaging unlikely to be detected by traditional measurement tools. An increase in muscle area with an inverse decrease in density suggests poor muscle quality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00408-023-00637-3.
format Online
Article
Text
id pubmed-10444650
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-104446502023-08-24 Analytic Morphomics in Myositis-Related Interstitial Lung Disease O’Mahony, Alexander T. Henry, Patrick J. Coghlan, Patrick Waldron, Michael Crowley, Claire Ryan, David Moore, Niamh Bennett, Deirdre M. O’Connor, Owen J. Maher, Michael M. Henry, Michael T. Lung Interstitial Lung Disease PURPOSE: Interstitial lung disease (ILD) is the most common non-musculoskeletal manifestation of idiopathic inflammatory myopathies (IIM). Identification of body composition change may enable early intervention to improve prognosis. We investigated muscle quantity and quality derived from cross-sectional imaging in IIM, and its relationship to ILD severity. METHODS: A retrospective cohort study assessing IIM of ILD patients (n = 31) was conducted. Two datasets separated in time were collected, containing demographics, biochemical data, pulmonary function testing and thoracic CT data. Morphomic analysis of muscle quantity (cross-sectional area) and quality (density in Hounsfield Units) on thoracic CT were analysed utilising a web-based tool allowing segmentation of muscle and fat. Bilateral erector spinae and pectoralis muscle (ESM&PM) were measured at defined vertebral levels. RESULTS: FVC and D(L)CO decreased but within acceptable limits of treatment response (FVC: 83.7–78.7%, p < 0.05, D(L)CO 63.4–60.6%, p < 0.05). The cross-sectional area of the PM and ESM increased (PM: 39.8 to 40.7 cm(2), p = 0.491; ESM: 35.2 to 39.5 cm(2), p = 0.098). Density significantly fell for both the PM and ESM (PM: 35.3–31 HU, p < 0.05; ESM: 38–33.7, p < 0.05). Subcutaneous fat area increased from 103.9 to 136.1 cm(2) (p < 0.05), while the visceral fat area increased but not reaching statistical significance. The change in PM density between time points demonstrated an inverse correlation with D(L)CO (p < 0.05, R =  − 0.49). CONCLUSION: Patients with IIM ILD demonstrated significant body composition changes on CT imaging unlikely to be detected by traditional measurement tools. An increase in muscle area with an inverse decrease in density suggests poor muscle quality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00408-023-00637-3. Springer US 2023-07-17 2023 /pmc/articles/PMC10444650/ /pubmed/37458801 http://dx.doi.org/10.1007/s00408-023-00637-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Interstitial Lung Disease
O’Mahony, Alexander T.
Henry, Patrick J.
Coghlan, Patrick
Waldron, Michael
Crowley, Claire
Ryan, David
Moore, Niamh
Bennett, Deirdre M.
O’Connor, Owen J.
Maher, Michael M.
Henry, Michael T.
Analytic Morphomics in Myositis-Related Interstitial Lung Disease
title Analytic Morphomics in Myositis-Related Interstitial Lung Disease
title_full Analytic Morphomics in Myositis-Related Interstitial Lung Disease
title_fullStr Analytic Morphomics in Myositis-Related Interstitial Lung Disease
title_full_unstemmed Analytic Morphomics in Myositis-Related Interstitial Lung Disease
title_short Analytic Morphomics in Myositis-Related Interstitial Lung Disease
title_sort analytic morphomics in myositis-related interstitial lung disease
topic Interstitial Lung Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444650/
https://www.ncbi.nlm.nih.gov/pubmed/37458801
http://dx.doi.org/10.1007/s00408-023-00637-3
work_keys_str_mv AT omahonyalexandert analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT henrypatrickj analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT coghlanpatrick analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT waldronmichael analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT crowleyclaire analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT ryandavid analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT mooreniamh analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT bennettdeirdrem analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT oconnorowenj analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT mahermichaelm analyticmorphomicsinmyositisrelatedinterstitiallungdisease
AT henrymichaelt analyticmorphomicsinmyositisrelatedinterstitiallungdisease